Elizabeth Ruth Plummer

1.7k total citations
69 papers, 1.3k citations indexed

About

Elizabeth Ruth Plummer is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Elizabeth Ruth Plummer has authored 69 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 35 papers in Molecular Biology and 21 papers in Cancer Research. Recurrent topics in Elizabeth Ruth Plummer's work include PARP inhibition in cancer therapy (22 papers), DNA Repair Mechanisms (15 papers) and Cancer Genomics and Diagnostics (12 papers). Elizabeth Ruth Plummer is often cited by papers focused on PARP inhibition in cancer therapy (22 papers), DNA Repair Mechanisms (15 papers) and Cancer Genomics and Diagnostics (12 papers). Elizabeth Ruth Plummer collaborates with scholars based in United Kingdom, United States and Germany. Elizabeth Ruth Plummer's co-authors include Nicola J. Curtin, Huw D. Thomas, Richard J. Edmondson, Asima Mukhopadhyay, Hilary Calvert, Yvette Drew, Zdeněk Hostomský, Evan A. Mulligan, Tomasz Zaremba and Michael Cole and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Elizabeth Ruth Plummer

66 papers receiving 1.3k citations

Peers

Countries citing papers authored by Elizabeth Ruth Plummer

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Ruth Plummer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Ruth Plummer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Ruth Plummer more than expected).

Fields of papers citing papers by Elizabeth Ruth Plummer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Ruth Plummer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Ruth Plummer. The network helps show where Elizabeth Ruth Plummer may publish in the future.

Co-authorship network of co-authors of Elizabeth Ruth Plummer

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Ruth Plummer. A scholar is included among the top collaborators of Elizabeth Ruth Plummer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Ruth Plummer. Elizabeth Ruth Plummer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors. 2024 ·Journal of Clinical Oncology ·Timothy A. Yap, Elizabeth Ruth Plummer, Anthony W. Tolcher, (unknown), Ioannis Gounaris, (unknown), (unknown), Christine Hicking, Jatinder Kaur Mukker, Johann S. de Bono	2
2	Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study. 2024 ·Journal of Clinical Oncology ·Axel Hauschild, Reinhard Dummer, Mario Santinami, Victoria Atkinson, Mario Mandalà, Barbara Merelli, Vanna Chiarion‐Sileni, Andrew Haydon, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Elizabeth Ruth Plummer, James Larkin, Monique Tan, (unknown), Paul Burgess, (unknown), Georgina V. Long	2
3	Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study 2023 ·Molecular Cancer Therapeutics ·Sarah P. Blagden, Stefan N. Symeonides, (unknown), (unknown), (unknown), In Hwa Um, (unknown), (unknown), Ying Zhang, David J. Harrison, (unknown), Elisabeth Oelmann, Jeffrey D. Bloss, Natalie Cook, (unknown), Elizabeth Ruth Plummer	0
4	A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies. 2022 ·Journal of Clinical Oncology ·Adam Sharp, (unknown), Sarah P. Blagden, Elizabeth Ruth Plummer, Daniel Hochhauser, Matthew Krebs, Simon Pacey, T.R. Jeffry Evans, Sarah Whelan, (unknown), (unknown), (unknown), Frank G. Basile, Johann S. de Bono, Hendrik‐Tobias Arkenau	8
5	Do Health Insurers Manage Their Medical Loss Ratios? At What Cost? 2021 ·Elizabeth Ruth Plummer, William F. Wempe	1
6	Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). 2021 ·Journal of Clinical Oncology ·Sarah Halford, Harriet S. Walter, Pam McKay, William Townsend, Kim Linton, Kathrin Heinzmann, I. Dragoni, (unknown), Gareth J. Veal, Alexandros Siskos, Hector C. Keun, Chris M. Bacon, Stephen R. Wedge, Martin J.S. Dyer, Elizabeth Ruth Plummer	26
7	Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial 2018 ·Annals of Oncology ·(unknown), Dirk Schadendorf, Lisa Zimmer, Sarah Danson, Ernest Marshall, Pippa Corrie, Matthew Wheater, Elizabeth Ruth Plummer, Cornelia Mauch, Claire Scudder, (unknown), Sharon Love, Soma Mohammed, Mark R. Middleton	15
8	First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker. 2018 ·Journal of Clinical Oncology ·Elizabeth Ruth Plummer, (unknown), Nicola Cresti, Aneta Suder, Yvette Drew, Peter Stephens, Marie L. Foegh, Steen Knudsen, Sharon McGonigle, Barbara Ink, Debashis Sarker	7
9	The EASI-SWITCH trial: Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis. 2016 ·Journal of Clinical Oncology ·(unknown), Ronan McMullan, Mike Clarke, Richard H. Wilson, Elizabeth Ruth Plummer, Anne Thomas, Rosemary A. Barnes, Richard Adams, Ian Chau, (unknown), Clíona McDowell, Ashley Agus, Ewan Brown, D. Storey, Daniel F. McAuley, Victoria Coyle	1
10	Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study. 2016 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), Piotr Pieniążek, (unknown), Rakesh Heer, R. McMenemin, Ian Pedley, Ashraf Azzabi, (unknown), Ross J. Maxwell, Elizabeth Ruth Plummer, J. Frew	2
11	Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies. 2015 ·Journal of Clinical Oncology ·Elizabeth Ruth Plummer, Henk M.W. Verheul, Sylvie Rottey, Karin Leunen, Guy Jérusalem, Christian Rolfo, Dorte Nielsen, L Rhoda Molife, Rebecca Kristeleit, Judith de Vos‐Geelen, Morten Mau‐Sørensen, Patricia M.M.B. Soetekouw, Carla van Herpen, Helen Swaisland, Anitra Fielding, Karen So, Wendy Bannister, Luc Dirix	1
12	Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules 2014 ·British Journal of Cancer ·J. C. Murray, Huw D. Thomas, P. Berry, Suzanne Kyle, Miranda Patterson, Christopher J. Jones, Gerrit Los, Zdeněk Hostomský, Elizabeth Ruth Plummer, Alan V. Boddy, Nicola J. Curtin	33
13	Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival 2012 ·Cancer Research ·Asima Mukhopadhyay, Elizabeth Ruth Plummer, Ahmed Elattar, (unknown), Bisha Fathamah Uzir, Jennifer E. Quinn, W. Glenn McCluggage, Perry Maxwell, (unknown), Nicola J. Curtin, Richard J. Edmondson	95
14	Defective homologous recombination in human cancers 2011 ·Cancer Treatment Reviews ·(unknown), Asima Mukhopadhyay, Elizabeth Ruth Plummer, Nicola J. Curtin, Richard J. Edmondson	54
15	Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials 2010 ·Cancer Chemotherapy and Pharmacology ·Tomasz Zaremba, Huw D. Thomas, Michael Cole, Elizabeth Ruth Plummer, Nicola J. Curtin	17
16	Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2 2010 ·JNCI Journal of the National Cancer Institute ·Yvette Drew, Evan A. Mulligan, (unknown), Huw D. Thomas, (unknown), Suzanne Kyle, Asima Mukhopadhyay, Gerrit Los, Zdeněk Hostomský, Elizabeth Ruth Plummer, Richard J. Edmondson, Nicola J. Curtin	191
17	Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma 2009 ·Clinical Cancer Research ·(unknown), Agata Rozanska, Huw D. Thomas, Evan A. Mulligan, Yvette Drew, Deborah J. Castelbuono, Zdeněk Hostomský, Elizabeth Ruth Plummer, Alan V. Boddy, Deborah A. Tweddle, Nicola J. Curtin, Steven C. Clifford	61
18	Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines 2009 ·British Journal of Cancer ·Tomasz Zaremba, Patrick Ketzer, Michael Cole, Sally A. Coulthard, Elizabeth Ruth Plummer, Nicola J. Curtin	57
19	Inhibition of poly(ADP-ribose) polymerase in cancer 2006 ·Current Opinion in Pharmacology ·Elizabeth Ruth Plummer	84
20	Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1 2005 ·Clinical Cancer Research ·Elizabeth Ruth Plummer, Mark R. Middleton, Christopher J. Jones, Anna L Olsen, Ian D. Hickson, Peter J. McHugh, Geoffrey P. Margison, Gail McGown, Mary Thorncroft, Amanda J. Watson, Alan V. Boddy, A. Hilary Calvert, Adrian L. Harris, David R. Newell, Nicola J. Curtin	83

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact